From Global News.

On Thursday, U.S. President Donald Trump unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular weight-loss treatments Zepbound and Wegovy.

The drugs are part of a new generation of popular medications known as GLP-1 receptor agonists, a class of injectable medications used to treat type 2 diabetes and obesity.

Trump added the drugs will be sold at the heavily reduced Most-Favoured-Nation price.

Most-Favoured-Nation (MFN) status is a principle in international trade that requires countries to treat all trading partners equally by applying the same trade terms and non-discriminatory standards.

For more info, please go to https://globalnews.ca
Subscribe to Global News Channel HERE: http://bit.ly/20fcXDc
Like Global News on Facebook HERE: http://bit.ly/255GMJQ
Follow Global News on X HERE: http://bit.ly/1Toz8mt
Follow Global News on Instagram HERE: https://bit.ly/2QZaZIB
#trump #uspolitics #GlobalNews